Advaxis Inc (ADXS)

8.34
NASDAQ : Health Care
Prev Close 8.18
Day Low/High 8.11 / 8.39
52 Wk Low/High 5.21 / 22.20
Avg Volume 696.30K
Exchange NASDAQ
Shares Outstanding 34.35M
Market Cap 280.96M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Aduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage Study

Aduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage Study

A type of common bacteria re-engineered by Aduro Biotech to engage the immune system to kill pancreatic cancer failed a mid-stage study, the company announced Monday.

These 5 Stocks Are Poised for Breakouts

These 5 Stocks Are Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Late Breaking Data At AACR Annual Meeting From Advaxis Phase 2 Study Of AXAL Highlights Potential Of The Company's Lm Technology™ Platform

Late Breaking Data At AACR Annual Meeting From Advaxis Phase 2 Study Of AXAL Highlights Potential Of The Company's Lm Technology™ Platform

First clinical data with AXAL to show evidence of cytotoxic T cell infiltration into the tumor immune microenvironment or TME for HPV-Positive oropharyngeal cancer

UPDATE -- Advaxis Hosts Research Reception To Review Late-Breaking AACR Abstract

UPDATE -- Advaxis Hosts Research Reception To Review Late-Breaking AACR Abstract

Researchers to Provide Updates on Evidence of Impact of Lm Immunotherapy in the Tumor Microenvironment

Advaxis Hosts Research Reception To Review Late-Breaking AACR Abstract

Advaxis Hosts Research Reception To Review Late-Breaking AACR Abstract

Researchers to Provide Updates on Evidence of Impact of Lm Immunotherapy in the Tumor Microenvironment

Survival Results With Advaxis HER2 Targeted Immunotherapy In Canine Osteosarcoma Published In Clinical Cancer Research

Survival Results With Advaxis HER2 Targeted Immunotherapy In Canine Osteosarcoma Published In Clinical Cancer Research

Data Shows Reduction in Metastatic Disease and Increased Survival

Dosing Begins In High Dose Expansion Cohort In Phase 2 Study Of Axalimogene Filolisbac In Patients With Recurrent Cervical Cancer

Dosing Begins In High Dose Expansion Cohort In Phase 2 Study Of Axalimogene Filolisbac In Patients With Recurrent Cervical Cancer

Expansion Phase of Study Follows Successful Completion of 2 Prior Escalating Dose Levels